120
Participants
Start Date
September 30, 2012
Primary Completion Date
August 31, 2016
Study Completion Date
August 31, 2016
SGI-110
Treatment of Choice (topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine)
Investigator chose to treat with either topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine
Carboplatin
Island Gynecologic Oncology, Brightwaters
Johns Hopkins Kimmel Cancer Center, Baltimore
Inova Fairfax Hospital, Falls Church
Duke Cancer Institute- Duke University Medical Center, Durham
Georgia Health Sciences University, Augusta
University of Florida Shands Cancer Center, Gainesville
University of Cincinnati Cancer Institute, Cincinnati
Melvin and Bren Simon Cancer Center- Indiana University, Indianapolis
University of Chicago, Chicago
Women's Cancer Care, Covington
Mary Crowley Medical Research Center, Dallas
Norris Comprehensive Cancer Center- University of Southern California, Los Angeles
Dana Farber Cancer Institute, Boston
Tom Baker Cancer Centre, Calgary
Juravinski Cancer Centre, Hamilton
Princess Margaret Hospital, Toronto
CHUM Gynecologie-Oncologie, Notre Dame Hospital, Montreal
Bristol Heamatology and Oncology Centre, Bristol
St. James Univesity Hospital - St. James Institute of Oncology, Leeds
Cambridge University Hospitals NHS Foundation and Trust, London
Univesity College Hospital, London
Imperial College Health Care NHS Trust-Garry Weston Centre, London
Mount Vernon Cancer Centre, Middlesex
Royal Marsden Foundation Trust, Sutton
Lead Sponsor
Astex Pharmaceuticals, Inc.
INDUSTRY